文献速递产科母胎医学

妊娠合并2019冠状病毒病患者口服奈玛特韦-利托那韦的临床结局

Oral Nirmatrelvir-Ritonavir Use and Clinical Outcomes in Pregnant Patients With Coronavirus Disease 2019 (COVID-19).
PubMed 文献 · Obstet Gynecol · 2023-11-14

本研究为回顾性队列研究,纳入症状出现5天内被建议服用奈玛特韦-利托那韦的孕妇,比较服药组(114例)与未服药组(323例)的产科和COVID-19结局。两组重症监护室入住均为零,服药组手术部位感染(3例[2.7%] vs 0例[0%],P=.02)和子痫前期(11例[9.6%] vs 12例[3.7%],P=.02)发生率显著更高,但事件数过少无法进行多变量建模。

要点

  • 服药组与未服药组均无重症监护室入住,药物耐受良好,无因副作用停药。
  • 服药组手术部位感染率3例(2.7%),未服药组0例(0%),P=.02。
  • 服药组子痫前期发生率11例(9.6%),未服药组12例(3.7%),P=.02。

核心结论

  • 这些初步数据可能对希望在妊娠期使用奈玛特韦-利托那韦的临床医生和患者具有安慰作用。

研究设计与样本

  • 回顾性队列研究,纳入严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染检测阳性、且在症状出现5天内被建议服用奈玛特韦-利托那韦的孕妇。
  • 服药组114例,未服药组323例,两组基线特征可比,包括两组疫苗接种率均高。

主要发现

  • 服药组手术部位感染3例(2.7%),未服药组0例(0%),P=.02。
  • 服药组子痫前期11例(9.6%),未服药组12例(3.7%),P=.02。
  • 两组均无重症监护室入住,无患者因副作用停药。
  • 多数产科和医学结局在两组间相似。

关键数值与推荐

  • 结局事件数过少,无法进行多变量建模。

临床怎么用

  • 作者认为这些初步数据可能对希望在妊娠期使用奈玛特韦-利托那韦的临床医生和患者具有安慰作用。

局限性

  • 结局事件数过少,无法进行多变量建模。
  • 这些为初步数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We conducted a retrospective cohort study of pregnant patients who tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection by RNA polymerase chain reaction test or home test who were counseled about taking nirmatrelvir-ritonavir if they were within 5 days of symptom onset. Obstetric and coronavirus disease 2019 (COVID-19) outcomes were compared between patients who did and did not take the medication. Overall, 114 individuals took nirmatrelvir-ritonavir and 323 did not. The cohorts were comparable, including high rates of vaccination in both groups. Nirmatrelvir-ritonavir was well-tolerated, with no patients discontinuing medication due to side effects. There were no intensive care unit admissions in either group. Most obstetric and medical outcomes were similar between those taking and not taking nirmatrelvir-ritonavir. Patients taking nirmatrelvir-ritonavir had significantly higher rates of surgical site infection (3 [2.7%] vs 0 [0%], P =.02) and preeclampsia (11 [9.6%] vs 12 [3.7%], P =.02). Outcome event numbers were too small for multivariable modeling. These preliminary data may be reassuring to clinicians and patients who would like to use nirmatrelvir-ritonavir in pregnancy.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Toure BB, Panakam A, Johns SL, et al. Oral Nirmatrelvir-Ritonavir Use and Clinical Outcomes in Pregnant Patients With Coronavirus Disease 2019 (COVID-19). Obstet Gynecol. 2023. PMID: 37963387. doi:10.1097/AOG.0000000000005471

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。